IrAE of any grade | 20 (32%) |
IrAE ≥ Grade 3/4 | 7 (11%) |
Systemic corticosteroid use | 5 (8%) |
Atezolizumab discontinuation due to IrAE | 7 (11%) |
Subgroup | Univariant HR | p | Multivariant HR | p | Reference category |
---|---|---|---|---|---|
0.861 (0.428-1.731) | 0.675 | ≥ 75 years | |||
2.883 (1.495-5.559) | 0.002 | 3.449 (1.358-8.761) | 0.009 | 2 or 3 | |
0.965 (0.502-1.853) | 0.914 | Yes | |||
0.319 (0.133-0.765) | 0.010 | 0.355 (0.131-0.961) | 0.042 | Yes | |
0.140 (0.032-0.604) | 0.008 | 0.113 (0.014-0.877) | 0.037 | > 6 months | |
0.566 (0.266-1.202) | 0.139 | Yes |
Platinum-treated N=44 (%) | Platinum-naïve N=18 (%) | |
---|---|---|
Type of response | All patients N=57 (%) | Patients with liver metastases N=16 (28%) | Platinum-naive N=17 (30%) | Platinum-treated N=40 (70%) | ECOG PS 0+1 N=33 (58%) | ECOG PS 2+3 N=24 (42%) |
---|---|---|---|---|---|---|
5 (9) | 0 (0) | 3 (17.5) | 2 (5) | 4 (12) | 1 (4.2) | |
7 (12) | 1 (6) | 3 (17.5) | 4 (10) | 5 (15) | 2 (8.3) | |
7 (12) | 4 (25) | 1 (6) | 6 (15) | 6 (18) | 1 (4.2) | |
38 (67) | 11 (69) | 10 (59) | 28 (70) | 18 (55) | 20 (83.3) |